4
Changes in Ownership
Adaptive Biotechnologies Corp Filed Acc 0001062993-25-002744
CEO and Chairman sold 470,368 shares at an average $8.47 ($3,985,754)
- CEO and Chairman acquired 470,368 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
ROBINS CHAD M · CEO and Chairman
Table I: Non-derivative
6 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2025-02-13 | Exercise or conversion : show line 1 in the form 10b5-1 | +100,287 | $6.32 | $633,814 | 2,676,988 | D |
| 2025-02-13 | Sale : show line 2 in the form 10b5-1 | −100,287 | $8.44 | $846,422 | 2,576,701 | D |
| 2025-02-14 | Exercise or conversion : show line 3 in the form 10b5-1 | +158,921 | $6.32 | $1,004,381 | 2,735,622 | D |
| 2025-02-14 | Sale : show line 4 in the form 10b5-1 | −158,921 | $8.46 | $1,344,472 | 2,576,701 | D |
| 2025-02-18 | Exercise or conversion : show line 5 in the form 10b5-1 | +211,160 | $6.32 | $1,334,531 | 2,787,861 | D |
| 2025-02-18 | Sale : show line 6 in the form 10b5-1 | −211,160 | $8.50 | $1,794,860 | 2,576,701 | D |
| Open-market sales · 470,368 sh · avg $8.47 · $3,985,754 | ||||||
Table II: Derivative
3 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2025-02-13 | Exercise or conversion : show line 7 in the form 10b5-1 Stock Option (right to buy) | −100,287 | 655,268 | D |
| 2025-02-14 | Exercise or conversion : show line 8 in the form 10b5-1 Stock Option (right to buy) | −158,921 | 496,347 | D |
| 2025-02-18 | Exercise or conversion : show line 9 in the form 10b5-1 Stock Option (right to buy) | −211,160 | 285,187 | D |
Loading xslF345X05/form4.xml…